Hauck & Aufhäuser Privatbankiers KGaA disclosed Gerresheimer (ETR:GXI), boosting its price target to 80.00EUR earlier today
- Updated: October 9, 2016
Reporting a potential upside of 0.09%, Hauck & Aufhäuser Privatbankiers KGaA upped the price target of Gerresheimer (ETR:GXI) to 80.00EUR
On 10/09/2016, Hauck & Aufhäuser Privatbankiers KGaA released a statement about Gerresheimer (ETR:GXI) upped the target price from 0.00EUR to 80.00EUR that suggested an upside of 0.09%.
Having a price of 73.37EUR, Gerresheimer (ETR:GXI) traded 0.00% even on the day. With the last stock price up 0.00% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. GXI has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Trade Volume held steady, with 0 shares of GXI changing hands on par with the typical 0
Recent Performance Chart
Gerresheimer has with a one year low of 0.00EUR and a one year high of 0.00EUR and has a market capitalization of 0 EUR.
General Company Details For Gerresheimer (ETR:GXI)
Gerresheimer AG is a Germany-based company that operates in the pharmaceuticals and health care industry. It is structured in three business segments: Plastic and Devices, Primary Packaging Glass and Life Science Research. The Company produces pharmaceutical packaging products, as well as drug-delivery systems made out of glass and plastics or a combination of both. Its product portfolio includes insulin pens, inhalers, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products. The Company operates approximately 40 production facilities in Europe, North America, South America and Asia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.